Apremilast

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Apremilast
   1. Pharmacist Assessment Report
   2. Apremilast: Known uses and market status in India
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. India Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Apremilast: Known uses and market status in India

Summary

The TxGNN deep-learning model has no candidate indication for Apremilast with a score of 0.99 or higher, so there is currently no new predicted indication. The drug’s own recorded uses are listed below. These are recorded uses, not model candidates.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	4
Evidence level	Not applicable
India Market Status	Listed in a compiled Indian medicine price dataset (19 of 19) – CDSCO approval status is not included in this data
Number of Listed Products	19 (valid: 19)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
behcet syndrome	licence in another country
oral ulcer	licence in another country
psoriasis	licence in another country
psoriatic arthritis	licence in another country

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

India Market Information

Licence	Product	Dosage form	Status
7841	Aplex Kit	packet of 13 tablets	Valid
5405	Aprotyl Starter Pack Kit	packet of 13 kit	Valid
819	Apraize 10 Tablet	strip of 4 tablets	Valid
9009	Aplavia 30mg Tablet	strip of 10 tablets	Valid
429	Aprezo 10 Tablet	strip of 4 tablets	Valid
1143	Alizap 30mg Tablet	strip of 10 tablets	Valid
3088	Aprenext 30mg Tablet	strip of 10 tablets	Valid
1264	Apxenta 30mg Tablet	strip of 10 tablets	Valid
176613	Pdlast Tablet	strip of 10 tablets	Valid
5135	Arthlast Tablet	strip of 10 tablets	Valid
196	Aprezo 30mg Tablet	strip of 10 tablets	Valid
185359	Riasis 30mg Tablet	strip of 10 tablets	Valid
1059	Apraize 20 Tablet	strip of 4 tablets	Valid
9320	Aprotyl 30mg Tablet	strip of 10 tablets	Valid
135583	Mprila Tablet	strip of 10 tablets	Valid
580	Aprezo 20 Tablet	strip of 4 tablets	Valid
3124	Apxenta 10 Tablet	strip of 10 tablets	Valid
667	Apraize 30 Tablet	strip of 10 tablets	Valid
3748	Apremist 30mg Tablet	strip of 10 tablets	Valid

Safety Considerations

• Drug Interactions: 75 interactions were identified in the interaction database. Major-level interactions include lumacaftor, fosphenytoin and apalutamide. Moderate-level interactions include dexamethasone, deferasirox, griseofulvin, bexarotene and bosentan, among others. Many of these appear to involve CYP3A4 inducers, which can lower apremilast exposure.
• Known adverse event: Headache is a recognized adverse event of apremilast, which is relevant to a migraine indication.

For warnings and contraindications, please refer to the package insert.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---